Novavax Expects to Be Ready for Covid Vaccine Delivery in Sept.

Novavax said it expects to be ready for the commercial delivery of a protein-based JN.1 Covid-19 vaccine in the US in September, pending authorization.

• An FDA panel recommended that Covid vaccines be updated to a monovalent JN.1-lineage composition for 2024-2025 and expressed a preference for the JN.1 strain, Novavax said in an emailed statement
• Panel acknowledged importance of having a protein-based option available at the start of vaccination season, alongside other alternatives
• NOTE: FDA Advisers Back Inclusion of JN1 Covid Variant in Shots

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the ...